Open Collections

Makuza, Jean Damascene; Jeong, Dahn; Binka, Mawuena; Adu, Prince Asumadu; Cua, Georgine; Yu, Amanda; Velásquez Garcia, Héctor Alexander; Alvarez, Maria; Wong, Stanley; Bartlett, Sofia; Karim, Mohammad Ehsanul; Yoshida, Eric; Ramji, Alnoor; Krajden, Mel; Janjua, Naveed Z.

Multidisciplinary Digital Publishing Institute

Data on the contribution of hepatitis B virus (HBV) infection and related comorbidities to liver-related mortality in Canada are limited. We assessed the concurrent impact of HBV infection, non-alcoholic fatty liver disease (NAFLD), and hepatitis C virus (HCV) coinfection on liver-related deaths in British Columbia (BC), Canada. We used data from the BC Hepatitis Testers Cohort (BC-HTC). We used Fine–Gray multivariable sub-distributional hazards models to assess the effect of HBV, NAFLD, and HCV coinfection on liver-related mortality, while adjusting for confounders and competing mortality risks. The liver-related mortality rate was higher among people with HBV infection than those without (2.57 per 1000 PYs (95%CI: 2.46, 2.69) vs. 0.62 per 1000 PYs (95%CI: 0.61, 0.64), respectively). Compared with the HBV negative groups, HBV infection was associated with increased liver-related mortality risk in almost all of the subgroups: HBV mono-infection (adjusted subdistribution hazards ratio (asHR) of 3.35, 95% CI 3.16, 3.55), NAFLD with HBV infection, (asHR 12.5, 95% CI 7.08, 22.07), and HBV/HCV coinfection (asHR 8.4, 95% CI 7.62, 9.26). HBV infection is associated with a higher risk of liver-related mortality, and has a greater relative impact on people with NAFLD and those with HCV coinfection. The diagnosis and treatment of viral and fatty liver disease are required to mitigate liver-related morbidity and mortality.

Article

eng

Vancouver : University of British Columbia Library

10.14288/1.0437973

Medicine, Faculty of; Non UBC; Population and Public Health (SPPH), School of

10.3390/v14112579

Faculty; Researcher; Graduate

DSpace